251 related articles for article (PubMed ID: 26547562)
1. Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years Experience.
Roe CR; Brunengraber H
Mol Genet Metab; 2015 Dec; 116(4):260-8. PubMed ID: 26547562
[TBL] [Abstract][Full Text] [Related]
2. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
[TBL] [Abstract][Full Text] [Related]
3. Tutorial: Triheptanoin and Nutrition Management for Treatment of Long-Chain Fatty Acid Oxidation Disorders.
Norris MK; Scott AI; Sullivan S; Chang IJ; Lam C; Sun A; Hahn S; Thies JM; Gunnarson M; McKean KN; Merritt JL
JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):230-238. PubMed ID: 33085788
[TBL] [Abstract][Full Text] [Related]
4. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
Gillingham MB; Heitner SB; Martin J; Rose S; Goldstein A; El-Gharbawy AH; Deward S; Lasarev MR; Pollaro J; DeLany JP; Burchill LJ; Goodpaster B; Shoemaker J; Matern D; Harding CO; Vockley J
J Inherit Metab Dis; 2017 Nov; 40(6):831-843. PubMed ID: 28871440
[TBL] [Abstract][Full Text] [Related]
5. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.
Vockley J; Marsden D; McCracken E; DeWard S; Barone A; Hsu K; Kakkis E
Mol Genet Metab; 2015; 116(1-2):53-60. PubMed ID: 26116311
[TBL] [Abstract][Full Text] [Related]
6. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride.
Roe CR; Sweetman L; Roe DS; David F; Brunengraber H
J Clin Invest; 2002 Jul; 110(2):259-69. PubMed ID: 12122118
[TBL] [Abstract][Full Text] [Related]
7. The safety of Lipistart, a medium-chain triglyceride based formula, in the dietary treatment of long-chain fatty acid disorders: a phase I study.
MacDonald A; Webster R; Whitlock M; Gerrard A; Daly A; Preece MA; Evans S; Ashmore C; Chakrapani A; Vijay S; Santra S
J Pediatr Endocrinol Metab; 2018 Mar; 31(3):297-304. PubMed ID: 29425111
[TBL] [Abstract][Full Text] [Related]
8. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.
Vockley J; Charrow J; Ganesh J; Eswara M; Diaz GA; McCracken E; Conway R; Enns GM; Starr J; Wang R; Abdenur JE; Sanchez-de-Toledo J; Marsden DL
Mol Genet Metab; 2016 Nov; 119(3):223-231. PubMed ID: 27590926
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.
Lund AM; Skovby F; Vestergaard H; Christensen M; Christensen E
J Inherit Metab Dis; 2010 Oct; 33(5):495-500. PubMed ID: 20066495
[TBL] [Abstract][Full Text] [Related]
10. [Determination of normal acylcarnitine levels in a healthy pediatric population as a diagnostic tool in inherited errors of mitochondrial fatty acid beta-oxidation].
Osorio JH; Pourfarzam M
An Pediatr (Barc); 2007 Dec; 67(6):548-52. PubMed ID: 18053519
[TBL] [Abstract][Full Text] [Related]
11. UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Humphrey R; Mayhew J; Bowden A; Zhang L; Cataldo J; Marsden DL; Kakkis E
Mol Genet Metab; 2017 Apr; 120(4):370-377. PubMed ID: 28189603
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Metabolic Defects in Fatty Acid Oxidation Using Peripheral Blood Mononuclear Cells Loaded with Deuterium-Labeled Fatty Acids.
Yuasa M; Hata I; Sugihara K; Isozaki Y; Ohshima Y; Hara K; Tajima G; Shigematsu Y
Dis Markers; 2019; 2019():2984747. PubMed ID: 30881520
[TBL] [Abstract][Full Text] [Related]
13. De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids.
Tucci S; Behringer S; Spiekerkoetter U
FEBS J; 2015 Nov; 282(21):4242-53. PubMed ID: 26284828
[TBL] [Abstract][Full Text] [Related]
14. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders.
Spiekerkoetter U; Bastin J; Gillingham M; Morris A; Wijburg F; Wilcken B
J Inherit Metab Dis; 2010 Oct; 33(5):555-61. PubMed ID: 20830526
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era.
Janeiro P; Jotta R; Ramos R; Florindo C; Ventura FV; Vilarinho L; Tavares de Almeida I; Gaspar A
Eur J Pediatr; 2019 Mar; 178(3):387-394. PubMed ID: 30617651
[TBL] [Abstract][Full Text] [Related]
16. Higher dietary protein intake preserves lean body mass, lowers liver lipid deposition, and maintains metabolic control in participants with long-chain fatty acid oxidation disorders.
Gillingham MB; Elizondo G; Behrend A; Matern D; Schoeller DA; Harding CO; Purnell JQ
J Inherit Metab Dis; 2019 Sep; 42(5):857-869. PubMed ID: 31295363
[TBL] [Abstract][Full Text] [Related]
17. Prospective treatment in carnitine-acylcarnitine translocase deficiency.
Pierre G; Macdonald A; Gray G; Hendriksz C; Preece MA; Chakrapani A
J Inherit Metab Dis; 2007 Oct; 30(5):815. PubMed ID: 17508264
[TBL] [Abstract][Full Text] [Related]
18. Urinary medium-chain acylcarnitines in medium-chain acyl-CoA dehydrogenase deficiency, medium-chain triglyceride feeding and valproic acid therapy: sensitivity and specificity of the radioisotopic exchange/high performance liquid chromatography method.
Schmidt-Sommerfeld E; Penn D; Rinaldo P; Kossak D; Li BU; Huang ZH; Gage DA
Pediatr Res; 1992 Jun; 31(6):545-51. PubMed ID: 1635814
[TBL] [Abstract][Full Text] [Related]
19. Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study.
Vockley J; Burton BK; Berry G; Longo N; Phillips J; Sanchez-Valle A; Chapman KA; Tanpaiboon P; Grunewald S; Murphy E; Lu X; Rahman S; Ray K; Reineking B; Pisani L; Ramirez AN
J Inherit Metab Dis; 2023 Sep; 46(5):943-955. PubMed ID: 37276053
[TBL] [Abstract][Full Text] [Related]
20. Major clinical events and healthcare resource use among patients with long-chain fatty acid oxidation disorders in the United States: Results from LC-FAOD Odyssey program.
Yang E; Kruger E; Yin D; Mace K; Tierney M; Liao N; Cibelli E; Drozd D; Ross N; Deering KL; Herout P; Harshaw Q; Shillington A; Thomas N; Marsden D; Kritzer A; Vockley J
Mol Genet Metab; 2024 May; 142(1):108350. PubMed ID: 38458123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
